The investment community will be closely monitoring the performance of GSK in its forthcoming earnings report. The company is expected to report EPS of $0.95, up 5.56% from the prior-year quarter.

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

GSK and S&P 500 Performance During 2007-08 Crisis GSK stock declined from $53 in September 2007 (pre-crisis peak) to around $28 in March 2009, as the markets bottomed out, implying it lost 48% of ...

The latest trading session saw GSK (GSK) ending at $36.19, denoting a -0.85% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily loss of 1.47% ...

GSK settles U.S. Zantac lawsuit, avoiding trial. Confidential settlements reinforce commitment to legal efficiency.

Price Performance & Valuation Year to date, GSK’s stock has gained 4.8% compared to the industry’s 20.0% growth. The stock has also underperformed the sector and the S&P 500.

GSK's native reporting currency is UK pounds, and shares are traded on the London Stock Exchange. GSK ADS, equivalent to 2 GSK shares, are traded on the NYSE in US$. The underlying performance of ...

For new and old investors, taking full advantage of the stock market and investing with confidence are ... which is more than double the S&P 500's performance over the same time frame. However, the ...

GSK plc (NYSE:GSK) is one of the most affordable yet financially rewarding healthcare stocks to buy right now, According to Insider Monkey’s database, 41 hedge funds are bullish on the stock ...